The 2014 LaskerKoshland Special Achievement Award will be presented to Mary-Claire King, a pioneer and visionary who revolutionized the use of genetics to identify disease genes, provide insights into human evolution, and champion human rights causes.
Progress in scientific understanding is not a continuous process. From time to time, a great idea (along with the evidence for it) provides an essential new perspective that opens new possibilities not envisioned before. In our time, the great idea that transformed understanding of biology is, of course, the central role of DNA as the repository and carrier of biological information from generation to generation. Once it became clear that genetic information is encoded as molecular sequences of nucleotides in the DNA that are translated into sequences of amino acid sequences in the proteins, it became possible to explain all of the fundamental elements of genetics and evolution in terms of molecular sequence. Moreover, much of the basic biology of health and disease could be understood better in the light of the flow of information from the genome to phenotype. The great idea that biology is about information and DNA, and that protein sequences were the nexus of this information was the work of a relatively few pioneers in the field now referred to as ''molecular biology,'' of whom Francis Crick and James Watson are by far the best known.
The latter half of the 20th century saw the penetration of the ideas around DNA and molecular sequences into all areas of biology. Very many scientists participated in what became relatively organized world-wide efforts to exploit molecular sequences. Most prominent among these was the concerted effort to determine the DNA sequence of human genomes and ultimately the genomes of the many other organisms on our planet. Another major effort was to determine and catalog the molecular sequence changes that result in human diseases, ranging from the rare inherited Mendelian traits (e.g., cystic fibrosis) to the all-too-common diseases like diabetes, cancer, and Alzheimer disease that appear to have a number of etiologic determinants, some inherited and some not. A third major effort was the exploitation of molecular sequence differences to understand evolution once it became clear that molecular sequence divergence is a logical and effective metric for measuring evolutionary distance. Finally, molecular sequence identities became the standard for forensic identification of individuals. Huge databases of such sequences are maintained and used by police and military authorities around the globe. Each of these efforts necessarily became associated with ''big science.'' Papers in the literature today typically feature not a handful but hundreds of authors.
However, a closer reading of the history will show that many of the key insights that fueled the progress that justified the ''big science'' efforts continued to be made by scientists working in the traditional academic way. Indeed, it seems that the flow of these ideas remains essential to making the ''big science'' productive.
Mary-Claire King, American Cancer Society Professor in the Departments of Medicine and Genome Sciences at the University of Washington, Seattle, who will be honored with the 2014 Lasker Koshland Special Achievement Award, repeatedly contributed insights involving molecular sequences and their uses. Although some of her work directly resulted in the large efforts cited above, she herself worked with a small group, only occasionally collaborating with some of the ''big science'' efforts. Her achievements had a transformational effect on the fields of molecular evolution, the genetics of breast cancer susceptibility in humans, and the use of DNA sequence similarity forensically to identify individuals. These achievements form the basis for the LaskerKoshland Special Achievement Award.
One hallmark of Dr. King's work is thorough mathematical and statistical analysis. Mathematics was Dr. King's undergraduate major; quantitative analysis was often critical to her success. Another hallmark of her work is intellectual courage. Each of her major successes was undertaken against the odds-often long odds. Finally, Dr. King is notable for her determination to find ways to apply her scientific knowledge and abilities for the greater good of society wherever possible.
Humans, Chimpanzees, Molecular Sequences, and Evolutionary Metrics Until the DNA era, the mechanism of evolutionary change was not accessible for serious study. Before 1950, there was not even a consensus on the chemical nature of genes. Molecular sequences changed all of that. In 1951, Fred Sanger determined the amino acid sequence of the B chain of bovine insulin (Sanger and Tuppy, 1951) . Soon thereafter, in 1956, Vernon Ingram discovered the single amino acid sequence change in human b-hemoglobin that causes sickle cell disease (Ingram, 1956 ). Many determinations of amino acid sequences, as well as the occasional mutants or polymorphisms in them, soon followed. These developments were accompanied by development of methods for assessing protein polymorphism by immunological and physical means as well.
In her doctoral dissertation with the late Allan Wilson, Mary-Claire King undertook ''.to obtain a quantitative and objective estimate of the 'genetic distance' between species.'' Her results, published in a nine-page lead article in Science magazine (King and Wilson, 1975) , assembled protein sequence and polymorphism data and analyzed them statistically to obtain an estimate of amino acid sequence divergence between human and chimpanzee. The result was striking: all of the methods that they used (including nucleic acid hybridization, which had just been introduced) agreed that the degree of difference in sequence at the protein level is about 1%. This degree of difference was inconsistent with the notion that the biological differences between the two species could be accounted for by protein differences. Instead, King and Wilson suggested that the differences were due to a ''.relatively small number of genetic changes in systems controlling the expression of genes..''
The extreme similarity of the chimpanzee and human molecular sequences was fully validated 30 years later by comparison of the full genomic sequences of the two species. The King and Wilson regulatory hypothesis is still, after all this time, the best explanation for the manifest differences in biological properties. Most significantly, the use of molecular sequences as the ''quantitative and objective estimate'' for evolutionary distance has become universally accepted.
Breast Cancer and the Genetics of Common Complex Diseases
Mary-Claire King began her studies of breast cancer families in 1974, shortly after finishing her Ph.D. She undertook to find genes that predispose to breast cancer even though there was no known method by which such a thing could be done. She began by searching for families in which a simple Mendelian pattern of inheritance could have caused the disease phenotype. She carried out a thorough segregation analysis that gave a maximum likelihood estimate that 4% of the thousands of families in a national cancer registry were segregating a highly penetrant autosomal-dominant gene that increased the risk of breast cancer about 10-fold by age 70 (Newman et al., 1988) .
It was not until 1980 that human gene mapping became practical (Botstein et al., 1980) . Then it was realized that DNA polymorphisms could be used as genetic markers and followed in studies of families for linkage between the DNA marker and a simply inherited Mendelian disease. It was not at all clear, however, how linkage mapping might contribute if the genetic determinants were more complicated than simple Mendelian. For example, if there are in the population several Mendelian loci conferring the same phenotype but unlinked to one another (i.e., locus heterogeneity), the mapping would quickly become difficult. Moreover, if in addition there were nongenetic causes for the same disease phenotype, the statistical signal for linkage might drown in the noise of larger numbers of nongenetic cases.
Undaunted, Dr. King went forward with linkage analysis in 23 families that she identified as most likely to be segregating an autosomal-dominant gene predisposing to breast cancer. She adopted the laborious methods introduced in 1980: restriction fragment length polymorphisms assessed by hybridization with radioactive probes on Southern blots. She applied a statistical test for heterogeneity that indicated that the 23 families were not all segregating the same gene. Faced with this heterogeneity, she had an insight: the families displaying early-onset disease might represent a more homogeneous cause. This turned out to be the key to success. It is important to note that sorting the families before linkage analysis was key: by taking age of onset as a prior condition, she avoided the necessity to make corrections for multiple hypothesis testing that would have vitiated the statistical significance of the finding.
Thus, Dr. King was able to use her insight and her command of the relevant statistical theory to separate signal from noise in the linkage data in a rigorous and robust way, resulting in the unambiguous mapping of a causative gene to the long arm of human chromosome 17. As can be seen from Figure 3 of her Science paper (Hall et al., 1990) , the cumulative LOD score (which is a measure of the evidence of linkage) is dependent on the age of onset of breast cancer. The gene evidently is the major cause of cancer in only those families that display the early age of onset; the statistic becomes negative (meaning no support for linkage) for those families with older ages of onset. The finding of the gene on chromosome 17q21 (which she named BRCA1) is the first example of detection and linkage mapping of severe mutations in common complex diseases. Dr. King's work became the model for this approach and for how the issues of multiple-hypothesis testing (the bane of ''big data'' analysis) can be overcome by a judicious choice of prior hypothesis.
Although the BRCA1 gene ultimately was cloned and sequenced by others, King's group continued their family studies. In 1994 they reported nine different BRCA1 germline mutations in ten extended families, confirming the identity of BRCA1 as the gene on chromosome 17q21 that predisposes to breast and ovarian cancer. By 1998, her group, among others, had found that BRCA1 actually accounts for only a few percent of all breast cancer, as predicted by her mathematical work a decade earlier, forcefully illustrating that the original success had depended upon King's decision to focus on only those families displaying early-onset disease. Six of the early-onset families segregate BRCA1, and the seventh segregates another gene now called BRCA2. The genes segregating in half of the remaining families have been found; the other half remain unknown.
Dr. King's work has made it possible to design diagnostic tests that today are in routine clinical practice. Women who carry BRCA1 mutations carry a roughly 10-fold elevated risk of breast or ovarian cancer and are examined more frequently for early signs of tumors. Many elect to undergo prophylactic salpingo-oophorectomy (removal of the fallopian tubes and ovaries) and/or prophylactic mastectomy, which for these women can be lifesaving. Dr. King's discovery of BRCA1 led the way to linkage studies of similar design that resulted in the finding of genes predisposing to many other kinds of cancer, notably colon cancer. Diagnostic methods that detect these alleles have also become routine in medical practice, and thousands of patients benefit.
Dr. King's focus on early-onset families provided a paradigm for finding genes underlying common complex diseases, namely to focus on the families with the most severe phenotypes. This paradigm has resulted in the discovery of genes predisposing to Alzheimer disease, coronary artery disease, and Parkinson's disease, among many others. As was the case for breast cancer, these discoveries help people in two ways: better understanding of the disease biology and better information for the treatment of the affected.
Mitochondrial DNA, Grandmothers, and Human Rights In the time of the notorious Argentinian dictatorship of 1975-1983, the Grandmothers of the Plaza de Mayo organized themselves in protest of the systematic murders of political opponents of the regime and their families. In addition to their justly famous demonstrations at the Plaza, they organized searches for the missing children of the ''disappeared,'' infants whom they had learned had been spared death but were instead distributed to unrelated families, often families of police or military complicit in the murders. After 1983, when redress became possible, at least in principle, what the Grandmothers most lacked was a convincing way to prove the identities of children once they found them. They understood enough genetics to intuit that there must be a way to do this by some kind of blood test. They searched out experts-first in Latin America and then, as their fame grew, worldwide.
The Grandmothers were referred to Mary-Claire King, initially as an authority who might be able to provide the robust statistical methods that could convince a court. At the time, the technology available was blood groups and histocompatibility markers. Dr. King quickly realized that, although the theoretical issues were easily solved, the actual determination required fresh blood and specific perishable immunological reagents. The Grandmothers, ever undaunted, identified a suitable laboratory in Buenos Aires, and Dr. King became the analyst for the first cases in which kidnapped children were identified and returned to their proper families by the courts.
The great step forward in solving the grandchildren's identification problem came when Dr. King found a way to apply direct DNA sequencing to it. The polymerase chain reaction (PCR) had recently been developed (but not yet commercialized), and Dr. King knew that there might be more than enough polymorphism in human mitochondrial DNA to serve for statistically secure identification. It soon became clear that this was a perfect solution, both theoretically and technically. Mitochondrial DNA is inherited strictly along the maternal lineage. All of the children of a given mother have identical copies of the mitochondrial DNA sequence, the mother has the same sequence as her mother, and so on. Further, any other relative from the maternal line will also have the same mitochondrial DNA sequence, so it is easy to find samples from a family for comparison even when the parents and grandparents are unavailable. Mitochondrial DNA is abundant in tissues, very hardy because of its small size, and readily amplified by PCR.
In this way, Dr. King became the technology leader in identification of human tissue. She pioneered the technology for extracting mitochondrial DNA from teeth, often the last intact tissues available for testing (Ginther et al., 1992) . The technology she developed for the Grandmothers of the Plaza de Mayo has come into general use by forensic scientists around the world. Dr. King gave the world the ability to securely identify victims of natural disaster, crime, and war, as well as kidnapping and political murder. Millions today know the fates of their loved ones because of this technology.
Dr. King's remarkable devotion to human genetics on the one hand and human rights on the other has continued to this day. For about the last 20 years, she has identified numerous genes that cause inherited hearing loss. She has done this as a part of a remarkable collaboration between Israeli and Palestinian geneticists. They study consanguineous families in which the probability of the emergence of a recessive trait is very high because of the inheritance of the same stretch of DNA from both parents. Such families are abundant in both Israel and Palestine. This collaboration, which has continued for decades, led to a joint PhD program between Bethlehem and Tel Aviv Universities.
Today, Dr. King is focused on the genetic and genomic analysis of another complex disease, schizophrenia. With her usual spirit of proceeding against the long odds, she has used genomic technology to show that (1) people with this disease are enriched for large deletions and duplications that appear to involve genes known to function in neurological development and (2) schizophrenic individuals often contain de novo mutations that disrupt genes with neurological functions.
To conclude, Dr. Mary-Claire King has provided creative scientific advances, both theoretical and practical, to the development of human molecular genetics from its earliest beginnings in the pre-DNA sequence era to the current day of large-scale genomics. In all of her work, she has focused not only on the science, but also on the people who benefit. It is entirely fitting that this exemplary scientist and citizen of the world be awarded the LaskerKoshland Special Achievement Award.
